https://orcid.org/0000-0002-0513-0336
Figures & data
Figure 1 Comparison of market share as a percentage of units contributed by biosimilars with the discount from the price of the reference product in 24 European countries and the US. European data [https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-Europe-2021.pdf]. US data [Barclay Global Pharmaceuticals; US Specialty Pharma. September 2022.] The US data are based on filgrastim, pegfilgrastim, trastuzumab, infliximab, and bevacizumab products till the third quarter of 2022.
![Figure 1 Comparison of market share as a percentage of units contributed by biosimilars with the discount from the price of the reference product in 24 European countries and the US. European data [https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-Europe-2021.pdf]. US data [Barclay Global Pharmaceuticals; US Specialty Pharma. September 2022.] The US data are based on filgrastim, pegfilgrastim, trastuzumab, infliximab, and bevacizumab products till the third quarter of 2022.](/cms/asset/61c917dd-2b73-4523-b645-b34764accf0d/dceo_a_12156840_f0001_c.jpg)
Figure 2 WAC Percent reduction of the biosimilars in the US. The WAC does not include gross-net sale discounts. [Source: https://www.iqvia.com; https://www.cms.gov].
![Figure 2 WAC Percent reduction of the biosimilars in the US. The WAC does not include gross-net sale discounts. [Source: https://www.iqvia.com; https://www.cms.gov].](/cms/asset/ffb8adb9-c4da-4a9c-9a1c-c5eb92570722/dceo_a_12156840_f0002_c.jpg)
Figure 3 Comparison of percent reduction of WAC price and percent adoption of biosimilars in the US. WAC Price does not include GTN discounts. The reference product is scored as 1.0.
Figure 4 The four reins are pulling back the adoption of biosimilars and artwork created by the Open AI platform, DALLE-2. (https://openai.com/product/dall-e-2).
Table 1 Cost per Gram of Monoclonal Antibodies in the Finished Product, as Reimbursed by CMS (Source: https://www.cms.gov]
Table 2 Critical Quality Attributes Classification